Details of the Drug

General Information of Drug (ID: DM4PUDW)

Drug Name
L-Glutamic Acid
Synonyms
Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Dietary supplement
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 147.13
Logarithm of the Partition Coefficient (xlogp) -3.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C5H9NO4
IUPAC Name
(2S)-2-aminopentanedioic acid
Canonical SMILES
C(CC(=O)O)[C@@H](C(=O)O)N
InChI
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
InChIKey
WHUUTDBJXJRKMK-VKHMYHEASA-N
Cross-matching ID
PubChem CID
33032
ChEBI ID
CHEMBL575060
CAS Number
56-86-0
UNII
3KX376GY7L
DrugBank ID
DB00142
TTD ID
D00ENY
VARIDT ID
DR00005
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter-like 3 (SLC22A13) DT38SZL S22AD_HUMAN Substrate [3]
Cystine/glutamate transporter (SLC7A11) DTKLMH6 XCT_HUMAN Substrate [4]
Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13) DTDSYAQ CMC2_HUMAN Substrate [5]
Sodium-independent aspartate/glutamate transporter 1 (SLC7A13) DTMWE5P S7A13_HUMAN Substrate [6]
Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12) DT85HYR CMC1_HUMAN Substrate [7]
Putative sodium-coupled neutral amino acid transporter 8 (SLC38A8) DT0UQDA S38A8_HUMAN Substrate [8]
Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10) DT2LGOY S38AA_HUMAN Substrate [9]
Excitatory amino acid transporter 4 (SLC1A6) DTV2AOB EAA4_HUMAN Substrate [10]
Excitatory amino acid transporter 1 (SLC1A3) DT9U216 EAA1_HUMAN Substrate [10]
Vesicular glutamate transporter 1 (SLC17A7) DTNK0FR VGLU1_HUMAN Substrate [11]
Vesicular glutamate transporter 2 (SLC17A6) DT5LHCR VGLU2_HUMAN Substrate [11]
Mitochondrial glutamate carrier 1 (SLC25A22) DTJCWP8 GHC1_HUMAN Substrate [12]
Mitochondrial glutamate carrier 2 (SLC25A18) DT3VZJO GHC2_HUMAN Substrate [13]
Excitatory amino acid transporter 5 (SLC1A7) DTBGZ8H EAA5_HUMAN Substrate [10]
Vesicular glutamate transporter 3 (SLC17A8) DTAGDH7 VGLU3_HUMAN Substrate [11]
Excitatory amino acid transporter 2 (SLC1A2) DT0VAI5 EAA2_HUMAN Substrate [14]
Excitatory amino acid transporter 3 (SLC1A1) DTJIRMD EAA3_HUMAN Substrate [15]
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [16]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [17]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Transient receptor potential cation channel subfamily M member 4 (TRPM4) OT354X8E TRPM4_HUMAN Gene/Protein Processing [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from L-Glutamic Acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Lisdexamfetamine DM6W8V5 Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [19]
Amphetamine DMSZQAK Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Amphetamine. Attention deficit hyperactivity disorder [6A05] [19]
Dextroamphetamine DMMIHVP Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Dextroamphetamine. Narcolepsy [7A20] [19]
Benzphetamine DMIJATC Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Benzphetamine. Obesity [5B80-5B81] [19]
Methamphetamine DMPM4SK Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Methamphetamine. Pain [MG30-MG3Z] [20]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1369).
2 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
3 SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
4 The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
5 Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
6 Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
7 Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588.
8 Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209.
9 The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
10 The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
11 Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
12 Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9.
13 The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18)
14 EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85.
15 Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
16 The role of the intracellular glutamate gradient in driving organic anion transporter function.
17 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
18 Depletion of 14-3-3 reduces the surface expression of Transient Receptor Potential Melastatin 4b (TRPM4b) channels and attenuates TRPM4b-mediated glutamate-induced neuronal cell death. Mol Brain. 2014 Jul 22;7:52. doi: 10.1186/s13041-014-0052-3.
19 Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
20 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]